Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B17 | O75795 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | SELL | P14151 | 1/20 | 0.31 |
| ▸ | SELP | P16109 | 1/20 | 0.31 |
| ▸ | SELE | P16581 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15517621 | 0.90 | UGT2B17 (0.37) | UGT2B17ALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL2046611 | 0.87 | ALDH1A1 (0.45) | UGT2B17ALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL11700915 | 0.83 | PSMB5 (0.46) | UGT2B17ALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL11793557 | 0.81 | PSMB5 (0.49) | UGT2B17ALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL10452977 | 0.81 | PSMB5 (0.49) | UGT2B17ALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL6669915 | 0.80 | ESR2 (0.40) | UGT2B17ALDH1A1MAPTKDM4ELMNA | |
| Methane SCHEMBL39470 | 0.80 | PSMB5 (0.47) | UGT2B17ALDH1A1MAPTKDM4ELMNA | |
| Ethane SCHEMBL6550192 | 0.80 | PSMB5 (0.47) | UGT2B17ALDH1A1MAPTKDM4ELMNA | |
| Methane SCHEMBL4437465 | 0.79 | PSMB5 (0.46) | UGT2B17ALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL24723271 | 0.75 | DAO (0.36) | UGT2B17ALDH1A1MAPTMAPK1PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2890677-B1 | N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2017-11-15 | — | — | EP | disclosed |
| US-9447083-B2 | N-acylhydrazone derivatives for selective T cell inhibitor and anti-lymphoid malignancy drug | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2016-09-20 | — | — | US | disclosed |
| US-9447083-B2 | N-acylhydrazone derivatives for selective T cell inhibitor and anti-lymphoid malignancy drug | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2016-09-20 | — | — | US | disclosed |
| US-9447083-B2 | N-acylhydrazone derivatives for selective T cell inhibitor and anti-lymphoid malignancy drug | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2016-09-20 | — | — | US | disclosed |
| US-20150252030-A1 | N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-09-10 | — | — | US | disclosed |
| US-20150252030-A1 | N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-09-10 | — | — | US | disclosed |
| US-20150252030-A1 | N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-09-10 | — | — | US | disclosed |
| EP-2890677-A1 | N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG | Chong Kun Dang Pharmaceutical Corp. (KR) | 2015-07-08 | — | — | EP | disclosed |
| WO-2014035149-A1 | N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2014-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252030-A1 | N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG | MALT1, MCL1, ACIN1 | UGT2B17 596/4885ALDH1A1 769/4885MAPT 4342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.